What is Afferent?
Afferent operates within the Pharmaceuticals industry, headquartered in Woburn, Massachusetts. The company, which employs between 20 to 49 individuals and generates between $10 million to $25 million in revenue, is focused on advancing pharmaceutical solutions. Its history of substantial investment, including a Series E round in 2007 and a Series C in 2003, indicates a trajectory of sustained development and market engagement.
How much funding has Afferent raised?
Afferent has raised a total of $128.5M across 3 funding rounds:
Series C
$23.5M
Series E
$35M
Series F
$70M
Series C (2003): $23.5M with participation from Scottish Equity Partners, LDC, Technomark Medical Ventures, GeneChem Inc., Temasek Holdings, West Deutsche Landesbank Girozentrale, ProVen VCT, ABN AMRO Fund, CLSA, and Avalon Ventures
Series E (2007): $35M, investors not publicly disclosed
Series F (2009): $70M supported by The Morningside Group, Ventech Solutions, MVM Life Science Partners, Sectoral Asset Management, and Ysios Capital Partners
Key Investors in Afferent
The Morningside Group
The Morningside Group, founded in 1986, is a private equity and venture capital firm with a focus on making investments and is managed by entrepreneurial investment professionals with deep industry knowledge. They are also committed to social responsibility.
MVM Life Science Partners
MVM Life Science Partners LLP invests in innovative healthcare companies, actively supporting businesses that enhance healthcare delivery through quality and cost-effective solutions. Their focus spans medical technology, pharmaceuticals, and digital health.
Ysios Capital Partners
Ysios Capital is a leading life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide, providing resources to ventures focused on developing novel therapies for high unmet medical needs.
What's next for Afferent?
The company's substantial enterprise-level funding, particularly the major strategic investment in its latest round, positions Afferent for significant expansion and innovation. This capital infusion is likely to fuel further research and development, market penetration, and strategic partnerships, solidifying its competitive edge in the pharmaceuticals landscape. The consistent investment history suggests a robust business model and a clear path toward achieving key milestones.
See full Afferent company page
